Displaying 31–40 of 292 research results
Jun 13, 2022
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
In its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
May 24, 2022
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
The company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
May 19, 2022
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
However, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
May 13, 2022
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
The device is designed for people with late-stage AMD who have no treatment options
May 9, 2022
Gene Knock-Out, Replacement Therapy for RP-RHO Performed Well in Lab Study
Editas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial
May 6, 2022
Promising Results from Lab Study of Gene Therapy for Cone-Rod Dystrophy
The study is an important step toward a clinical trial of the approach
May 2, 2022
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
The company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
Apr 25, 2022
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
The Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
Apr 1, 2022
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
The drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors